BD Expanding Safety Needle Technology Platform With Saf-T-Med Buy
This article was originally published in The Gray Sheet
Executive Summary
Becton Dickinson plans to initiate marketing feedback studies of Saf-T-Med's Easy Safe retracting needle syringe within 12 months, the company says.
You may also be interested in...
Becton Dickinson Signs Sharps Agreement But Predicts Disappointing Quarter
Becton Dickinson's safety engineered "sharps" program with Kaiser Permanente, announced June 16, signals the initial success of a strategy that is expected to carry the company out of its recent warnings of slower growth.
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.